Study analysis · Frontiers in Physiology · 2021
Estrogen patches made women gain nearly 8% more thigh muscle—just by lifting weights.
Women who wore estrogen patches and lifted weights grew almost twice as much thigh muscle as those who only lifted weights.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a fair test where half the women got a special patch and half got a fake one, then everyone did the same strength training. The women with the real patch gained more muscle, so we can say the patch probably helped. But we can't say it works for everyone—just this group of women who were newly postmenopausal.
What’s the bottom line?
After menopause, women lose muscle faster. This study gave some women estrogen patches and others fake patches, then had everyone do weight training for 12 weeks.
How strong is this study?
This study was done really well because no one knew who got the real patch or the fake one, and everyone did the same workouts. That makes the results trustworthy. But since only 31 women were in the study, we can't be 100% sure it would work the same for thousands of other women.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
79 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=31)+2.9/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 575 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This study is a randomized controlled trial with double blinding and a control group, which allows for causal inference between transdermal estrogen therapy and increased muscle mass gains. However, the small sample size (n=31) and potential for residual confounding (e.g., unmeasured dietary or activity differences) limit the certainty of the causal claim.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the study text. The study appears independently conducted with no apparent industry ties or financial conflicts.
Independent Analysis Safeguards
- Double-blinded randomized controlled design
- MRI and DXA scans performed by blinded researcher using standardized protocols
- Study approved by ethical committee and registered at clinicaltrials.gov
Although the transdermal estrogen patches (Vivelle dot) were manufactured by Novartis and placebo patches by Matas, there is no disclosure of funding, author affiliations with these companies, or funder involvement in study design, analysis, or publication. The absence of a COI or funding statement is a limitation, but no evidence of bias or conflict is present in the reported methods or results.
Key takeaways
- 01
Women with estrogen patches gained 7.9% more thigh muscle and 5.5% more lean body mass than those with placebo patches.
- 02
Their handgrip strength also improved, but leg strength and jumping power did not improve more than the placebo group.
- 03
Yes — gaining nearly 8% more muscle in the thighs with estrogen patches, while doing the same workouts, is a meaningful boost for women trying to stay strong after menopause.
Surprising findings
- Handgrip and finger strength improved only in the estrogen group, even though training didn’t target those muscles.Most assume strength gains come only from direct training—this suggests estrogen has a systemic neuromuscular effect, possibly improving nerve signaling or motor unit recruitment.
- The placebo group improved more in the sit-to-stand test than the estrogen group.Since the estrogen group gained more muscle, it was expected they’d outperform in functional tests—but the opposite happened, suggesting technique or learning effects may have outweighed physiological advantages.
Practical takeaways
If you're a postmenopausal woman doing resistance training, talk to your doctor about whether transdermal estrogen therapy could help you build more lean muscle.
This study used a specific dose (100 μg) in early postmenopausal women (≤5 years); results may not apply to older women or those with health risks like clotting disorders or breast cancer history.
high confidenceWhy this study matters
Estrogen = Muscle Growth Booster
Women using transdermal estrogen patches (100 μg 17β-estradiol) alongside 12 weeks of resistance training gained 7.9% more quadriceps muscle mass and 5.5% more whole-body fat-free mass than those on placebo, despite identical workouts.
This suggests hormone therapy isn't just for hot flashes—it could be a powerful tool for women fighting age-related muscle loss, helping them stay strong, independent, and injury-resistant after menopause.
Handgrip Strength Surprise
Only the estrogen group improved handgrip strength (28.3 kg → 30.0 kg), even though their training didn’t target hands—suggesting estrogen may boost neuromuscular efficiency beyond just muscle size.
Stronger hands mean better grip for daily tasks—opening jars, carrying groceries, preventing falls. This hints estrogen might improve brain-muscle communication, not just tissue growth.
No Boost in Leg Power or Squat Strength
Despite gaining more muscle, the estrogen group didn’t outperform the placebo group in leg press, jumping, or knee extension strength—muscle size didn’t automatically mean strength gains.
This flips the script: Bigger muscles don’t always mean stronger. It suggests estrogen helps build muscle, but not necessarily how efficiently the nervous system uses it.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
After menopause, women lose muscle faster. This study gave some women estrogen patches and others fake patches, then had everyone do weight training for 12 weeks.
Research results
Women with estrogen patches gained 7.9% more thigh muscle and 5.5% more lean body mass than those with placebo patches. Their handgrip strength also improved, but leg strength and jumping power did not improve more than the placebo group.
What this means - more context
Yes — gaining nearly 8% more muscle in the thighs with estrogen patches, while doing the same workouts, is a meaningful boost for women trying to stay strong after menopause.
This study tested whether transdermal estrogen therapy enhances muscle mass gains from resistance training in early postmenopausal women.
In a 12-week double-blind RCT, early postmenopausal women receiving transdermal estrogen (100 μg 17β-estradiol) plus resistance training showed significantly greater increases in quadriceps muscle cross-sectional area (7.9% vs. 3.9%) and whole-body fat-free mass (5.5% vs. 2.9%) than those receiving placebo plus training. Handgrip strength improved only in the estrogen group, but maximal knee strength, leg power, and jumping did not differ between groups.
Methods Used
Thirty-one healthy, untrained postmenopausal women (≤5 years postmenopause) were randomly assigned to 12 weeks of supervised resistance training plus either transdermal estrogen (n=15) or placebo (n=16). Primary outcome: quadriceps femoris cross-sectional area via MRI; secondary outcomes: fat-free mass (DXA), strength, and functional tests.
Main Finding
Transdermal estrogen therapy significantly enhanced muscle mass gains from resistance training, increasing quadriceps cross-sectional area by 7.9% (vs. 3.9% in placebo) and whole-body fat-free mass by 5.5% (vs. 2.9%), with a significant improvement in handgrip strength only in the estrogen group.
Confidence Level
High — double-blind, randomized, controlled trial with objective imaging (MRI, DXA), high adherence (100%), and statistically significant effect sizes reported with p<0.05.
Study Flags
Red Flags
- •Small sample size (n=31)
- •Self-reported protein intake with high non-compliance (only 11/31 provided valid data)
- •Lack of non-training control groups to isolate estrogen-only effects
Surprising Findings
Handgrip and finger strength improved only in the estrogen group, even though training didn’t target those muscles.
Most assume strength gains come only from direct training—this suggests estrogen has a systemic neuromuscular effect, possibly improving nerve signaling or motor unit recruitment.
Practical Takeaways
If you're a postmenopausal woman doing resistance training, talk to your doctor about whether transdermal estrogen therapy could help you build more lean muscle.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 575 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a fair test where half the women got a special patch and half got a fake one, then everyone did the same strength training. The women with the real patch gained more muscle, so we can say the patch probably helped. But we can't say it works for everyone—just this group of women who were newly postmenopausal.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Double-blinded, randomized controlled trial design
- High adherence to intervention (100% training completion)
- Use of objective measures (MRI, DXA) for primary outcomes
Weaknesses
- Small sample size (n=31) limits statistical power
- Only 11 participants provided valid dietary data, limiting nutritional analysis
- No non-training control groups to isolate estrogen effect from training effect
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
After menopause, women lose muscle faster. This study gave some women estrogen patches and others fake patches, then had everyone do weight training for 12 weeks.
Research results
Women with estrogen patches gained 7.9% more thigh muscle and 5.5% more lean body mass than those with placebo patches. Their handgrip strength also improved, but leg strength and jumping power did not improve more than the placebo group.
What this means - more context
Yes — gaining nearly 8% more muscle in the thighs with estrogen patches, while doing the same workouts, is a meaningful boost for women trying to stay strong after menopause.
This study tested whether transdermal estrogen therapy enhances muscle mass gains from resistance training in early postmenopausal women.
In a 12-week double-blind RCT, early postmenopausal women receiving transdermal estrogen (100 μg 17β-estradiol) plus resistance training showed significantly greater increases in quadriceps muscle cross-sectional area (7.9% vs. 3.9%) and whole-body fat-free mass (5.5% vs. 2.9%) than those receiving placebo plus training. Handgrip strength improved only in the estrogen group, but maximal knee strength, leg power, and jumping did not differ between groups.
Methods Used
Thirty-one healthy, untrained postmenopausal women (≤5 years postmenopause) were randomly assigned to 12 weeks of supervised resistance training plus either transdermal estrogen (n=15) or placebo (n=16). Primary outcome: quadriceps femoris cross-sectional area via MRI; secondary outcomes: fat-free mass (DXA), strength, and functional tests.
Main Finding
Transdermal estrogen therapy significantly enhanced muscle mass gains from resistance training, increasing quadriceps cross-sectional area by 7.9% (vs. 3.9% in placebo) and whole-body fat-free mass by 5.5% (vs. 2.9%), with a significant improvement in handgrip strength only in the estrogen group.
Confidence Level
High — double-blind, randomized, controlled trial with objective imaging (MRI, DXA), high adherence (100%), and statistically significant effect sizes reported with p<0.05.
Study Flags
Red Flags
- •Small sample size (n=31)
- •Self-reported protein intake with high non-compliance (only 11/31 provided valid data)
- •Lack of non-training control groups to isolate estrogen-only effects
Surprising Findings
Handgrip and finger strength improved only in the estrogen group, even though training didn’t target those muscles.
Most assume strength gains come only from direct training—this suggests estrogen has a systemic neuromuscular effect, possibly improving nerve signaling or motor unit recruitment.
Practical Takeaways
If you're a postmenopausal woman doing resistance training, talk to your doctor about whether transdermal estrogen therapy could help you build more lean muscle.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 575 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a fair test where half the women got a special patch and half got a fake one, then everyone did the same strength training. The women with the real patch gained more muscle, so we can say the patch probably helped. But we can't say it works for everyone—just this group of women who were newly postmenopausal.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Double-blinded, randomized controlled trial design
- High adherence to intervention (100% training completion)
- Use of objective measures (MRI, DXA) for primary outcomes
Weaknesses
- Small sample size (n=31) limits statistical power
- Only 11 participants provided valid dietary data, limiting nutritional analysis
- No non-training control groups to isolate estrogen effect from training effect
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was done really well because no one knew who got the real patch or the fake one, and everyone did the same workouts. That makes the results trustworthy. But since only 31 women were in the study, we can't be 100% sure it would work the same for thousands of other women.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
79 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=31)+2.9/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 575 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This study is a randomized controlled trial with double blinding and a control group, which allows for causal inference between transdermal estrogen therapy and increased muscle mass gains. However, the small sample size (n=31) and potential for residual confounding (e.g., unmeasured dietary or activity differences) limit the certainty of the causal claim.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the study text. The study appears independently conducted with no apparent industry ties or financial conflicts.
Independent Analysis Safeguards
- Double-blinded randomized controlled design
- MRI and DXA scans performed by blinded researcher using standardized protocols
- Study approved by ethical committee and registered at clinicaltrials.gov
Although the transdermal estrogen patches (Vivelle dot) were manufactured by Novartis and placebo patches by Matas, there is no disclosure of funding, author affiliations with these companies, or funder involvement in study design, analysis, or publication. The absence of a COI or funding statement is a limitation, but no evidence of bias or conflict is present in the reported methods or results.